Muscle-Directed Gene Transfer and Transient Immune Suppression Result in Sustained Partial Correction of Canine Hemophilia B Caused by a Null Mutation

This publication has 24 references indexed in Scilit:

• Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
  Blood, 2001
• Posttranslational modifications of recombinant myotube-synthesized human factor IX
  Blood, 2001
• Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
  Nature Genetics, 2000
• Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver
  Molecular Therapy, 2000
• Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
  Nature Medicine, 1999
• Persistent expression of canine factor IX in hemophilia B canines
  Gene Therapy, 1999
• Gene therapy for the hemophilias
  Proceedings of the National Academy of Sciences, 1999
• Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
  Nature Medicine, 1999
• Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
  Proceedings of the National Academy of Sciences, 1997
• Factor IX:Molecular structure, epitopes, and mutations associated with inhibitor formation
  Published by Springer Nature ,1995